{
    "organizations": [],
    "uuid": "3327c04dd75fce3d7185dc1ad2f8f1f2688d81ef",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-eagle-pharmaceuticals-reports-q4-e/brief-eagle-pharmaceuticals-reports-q4-eps-of-0-58-idUSASB0C7CW",
    "ord_in_thread": 0,
    "title": "BRIEF-Eagle Pharmaceuticals Reports Q4 EPS Of $0.58",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 26 (Reuters) - Eagle Pharmaceuticals Inc:\n* EAGLE PHARMACEUTICALS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS\n* Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.00\n* Q4 EARNINGS PER SHARE $0.58 * Q4 REVENUE $46.8 MILLION VERSUS $81.1 MILLION * Q4 EARNINGS PER SHARE VIEW $1.00, REVENUE VIEW $52.9 MILLION -- THOMSON REUTERS I/B/E/S\n* 2018 RESEARCH AND DEVELOPMENT EXPENSE IS EXPECTED TO BE IN RANGE OF $46 MILLION TO $50 MILLION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-02-26T20:08:00.000+02:00",
    "crawled": "2018-02-27T15:08:08.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "eagle",
        "pharmaceutical",
        "inc",
        "eagle",
        "pharmaceutical",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "result",
        "q4",
        "adjusted",
        "earnings",
        "per",
        "share",
        "q4",
        "earnings",
        "per",
        "share",
        "q4",
        "revenue",
        "million",
        "versus",
        "million",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "research",
        "development",
        "expense",
        "expected",
        "range",
        "million",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}